BioXcel Therapeutics向FDA提交Igalmi®补充新药申请 寻求拓展家用适应症

美股速递
Jan 20

BioXcel Therapeutics公司已向美国食品药品监督管理局提交了Igalmi®的补充新药申请。此次申请旨在扩大该药物的标签适应症范围,将其使用场景延伸至家庭环境。这一举措若获批准,将有望为患者在居家场景下管理相关症状提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10